These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 15772741)

  • 1. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
    Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
    Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
    Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
    Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
    Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
    J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Skoromets A; Stolyarov I; Bass A; Sullivan H; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Neurology; 2012 Apr; 78(14):1069-78. PubMed ID: 22442431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis.
    Coppola G; Lanzillo R; Florio C; Orefice G; Vivo P; Ascione S; Schiavone V; Pagano A; Vacca G; De Michele G; Morra VB
    Eur J Neurol; 2006 Sep; 13(9):1014-21. PubMed ID: 16930370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
    Clanet M; Kappos L; Hartung HP; Hohlfeld R;
    Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.